Disease Immune Response Medical Schools 
Drug Target Review
APRIL 26, 2023
Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.
Drug Target Review
DECEMBER 28, 2023
These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. Patients with high numbers of clonal neoantigens show improved disease-free survival.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
JULY 26, 2022
Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. It gets its name from the intestinal mucus it breaks down.
Drug Target Review
JANUARY 15, 2024
This produces a great advantage in infectious disease, as it becomes difficult for a virus to adapt and spread from person to person, because each person’s HLA array is genetically distinct. Therefore, therapeutically useful tumour antigens represent a tiny fraction of the genes expressed by a tumour cell.
The Pharma Data
DECEMBER 15, 2020
A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.
Broad Institute
JUNE 14, 2023
She is also director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and provost for medical affairs of Cornell University. Glimcher, M.D.,
Broad Institute
AUGUST 7, 2023
Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.
Expert insights. Personalized for you.
98 
Let's personalize your content